SWOT Analysis for Seres Therapeutics Inc

Companies with 10% increase in share price over three months, with rising net profit growth
Consistent Highest Return Stocks over Five Years
Strong Momentum: Price above short, medium and long term moving averages
Relative Outperformance versus Industry over 1 Month
Momentum Play Screener - Weekly Strategy
Relative Outperformance versus Industry over Half Year (6 Months)
Relative Outperformance versus Industry over the Quarter (3 Months)
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Overbought by Money Flow Index (MFI)
Near 52 Week High
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Stock gained more than 20% in one month
Annual Net Profits improving for last 2 years
Stock with Low PE (PE < = 10)
Stocks near 52 Week High with Significant Volumes
Highest Recovery from 52 Week Low
Stocks Outperforming their Industry Price Change in the Quarter

Promoter decreasing their shareholding
Companies with High Debt
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Top Losers
Low Piotroski Score : Companies with weak financials
Declining Net Cash Flow : Companies not able to generate net cash
Top Losers